IAS 2021 11th IAS Conference on HIV Science 18-21 July 2021
Virtuell


Die Tagung der Internationalen Aids Society ist traditionell wissenschaftlich ausgerichtet. Sie findet virtuell statt, es gibt jedoch einen „German Hub“ mit Präsenz in Berlin. Hier der Link zum Kongress.  

ist offizieller Media-Partner der IAS-Konferenz


HCV-Elimination: Kaum noch Hepatitis bei Menschen mit HIV in Holland

FLAIR: CAB+RPV 124 Wochen

CAB+RPV: Prädiktoren für virologisches Versagen

SALSA: Switch auf DTG/3TC

Dolutegravir vs Darunavir bei akuter HIV-Infektion

Dolutegravir/Rilpivirin bei K103

Dolutegravir kein Einfluss auf Neuralrohrdefekte

Islatravir/Doravirin zu 96 Wochen

PrEP – Cave TDF-Resistenzentwicklung

Islatravir Q1M zur PrEP

Lenacapavir als Firstline

Lenacapavir als Salvage

Tuberkulose: Neues Regime für hochresistente Tuberkulose

HIV: Immunmodulation zur funktionellen Heilung

COVID-19: HIV ist ein Risikofaktor für schweren Verlauf

Powerpoint Download PDF-Download IAS2021 Publikationen Gilead Sciences

Acosta-R_Achievement-of-TND--Target-Not-Detected--in-BFTAF-treatment-naive-trials-1489---1490_IAS-2021_PEB150-Poster.pptx

Andreatta-K_Long-term-efficacy-in-BFTAF-switch-study-1844-with-preexisting-resistance-and-blips_IAS-2021_PEB172-Poster.pptx

Arribas-J_Long-term-outcome-in-BFTAF-treatment-naive-trials-1489---1490-at-Wk192_IAS-2021_PEB151-Poster.pptx

Beauchamp-G_Trust-in-PrEP-provider-associated-with-accurate-self-reported-adherence-in-young-femals-in-sub-Saharan-Africa_IAS-2021_PED0398.pdf

Bekerman-E_Efficacy-of-Capsid-Inhibitor-as-PrEP-in-vaginal-SHIV-challenge-model-in-macaques_IAS-2021_PECLB24.pptx

Cai-Y_Proteomic-evaluation-of-immune-response-induced-by-TLR-7-agonist-Vesatolimod_IAS-2021_OAA0304.pptx

Delany-Moretlwe-S_Laboratory-analysis-of-HIV-infections-in-HPTN084---LA-CAB-as-PrEP-in-women_IAS-2021_PEC355.pdf

Epting-M_HIV-testing-strategies-in-jails_IAS-2021_PED435.pdf

Greenberg-L_INSTI-use-and-cancer-incidence_IAS-2021_PEB143.pdf

Hechter-R_Risk-of-HIV-infection--knowledge-and-use-of-PrEP-among-trans-and-non-binary-adults_IAS-2021_PEC290.pdf

Imbert-E_Preference-for-care-engagement-among-persons-with-HIV-experiencing-homelessness-or-unstable-housing_IAS-2021_OAD0603.pdf

Kumar-P_BFTAF-switch-trial-BRAAVE-2020-in-black-African-Americans-at-Wk72---impact-of-COVID19_IAS-2021_PEB161-Poster.pptx

Liu-G_HPV-increases-HIV-risk-in-African-women_IAS-2021_OAC0404.pdf

Maggiolo-F_BFTAF-switch-trial-4449-in-PLWH-65-and-older-at-Wk96_IAS-2021_PEB160-Poster.pptx

Makanani-B_Safety-trial-of-Dapivirine-Vaginal-Ring-and-oral-FTCTDF-in-late-pregnancy_IAS-2021_PECLB26.pdf

Marquez-L_Modeling-analysis-of-HCV-elimination-among-HIV-positive-MSM-in-Germany-from-NoCo-Study_IAS-2021_PEB092.pdf

Mavarani-L_Change-in-body-weight-in-aging-PLWH-compared-with-general-population-in-German-Ruhr-area-over-5-years_IAS-2021_PEB125.pdf

Moldt-B_Reservoir-size-and-bNAb-susceptibility-in-acute-and-chronic-HIV-infection_IAS-2021_OAA0405.pptx

Moodley-D_CAP016-PrEP-in-Pregnancy-Study-evaluating-PrEP-in-Pregnany-and-during-Lactation_IAS-2021_PEC355.pdf

Moore-M_Modeled-efficacy-of-LA-CAB-as-PrEB-in-HPTN084-verus-a-conterfactual-background-HIV-incidence_IAS-2021_OAC0105.pdf

Parkin-N_Definition-of-counter-factual-HIV-infection-rate-for-new-PrEP-trials_IAS-2021_PEC307.pptx

Sacks-NC_Adherence-to-PrEP-with-FTAF-or-FTDF-from-claims-database-in-the-US_IAS-2021_OAC0103.pptx

Spinner-C_FTAF-for-PrEP-in-DISCOVER-at-OLE-phase-Wk48_IAS-2021_OALC0501.pptx

Tao-L_PrEP-utilization-during-COVID-19-in-the-US_IAS-2021_OAC0203.pptx

Wright-E_Lower-HIV-reservoirs-in-individuals-with-higher-CD4-prior-ART-in-START_IAS-2021_PEBLB13.pdf

Xu-J_Effectiveness-and-adherence-of-daily-or-event-driven-PrEP-in-China-in-CROPrEP-study_IAS-2021_PECLB23.pdf


IAS 2021 Publikationen ViiV

DOLUTEGRAVIR
Switching to the 2-drug regimen of dolutegravir/lamivudine (DTG/3TC) fixed-dose combination (FDC) is non-inferior to continuing a 3-drug regimen through 24 weeks in a randomized clinical trial (SALSA) J M Llibre Oral Presentation View Abstract
View Presentation
Download Presentation
Comparison of Viral Replication for the 2-Drug Regimen (2DR) of Dolutegravir/Lamivudine (DTG/3TC) versus a 3/4-Drug Tenofovir Alafenamide-based regimen (TBR) in the TANGO Study through Week 96 R Wang On-Demand Oral Abstract Presentation View Abstract
View Presentation Download Presentation
Metabolic health outcomes at week 96 in the TANGO Study, comparing a switch to DTG/3TC versus maintenance of TAF-based regimens J van Wyk E-Poster View Abstract
View Presentation
Download Presentation
Feasibility, Efficacy, and Safety of Dolutegravir/Lamivudine (DTG/3TC) as a First-line Regimen in a Test-and-Treat Setting for Newly Diagnosed People Living With HIV (PLWH): 48-Week Results of the STAT Study C Rolle E-Poster View Abstract
View Presentation Download Presentation
DTG+3TC in GEMINI-1&-2: HIV-1 replication at <50 c/mL and VL blips through 144 weeks M Underwood E-Poster View Abstract
View Presentation
Download Presentation
Integrase strand transfer inhibitor (INSTI) use and cancer incidence L Greenberg, on behalf of the RESPOND study group E-Poster View Abstract
Download Presentation
CABOTEGRAVIR+RILPIVIRINE-Long-Acting for Treatment
Week 124 results of the randomized, open-label, phase 3 FLAIR study evaluating long-acting cabotegravir + rilpivirine for treatment in adults with HIV-1 infection (ITT-E population) C Orkin On-Demand Oral Abstract Presentation View Abstract
View Presentation
Download Presentation
CUSTOMIZE: Overall results from a hybrid III implementation-effectiveness study examining implementation of cabotegravir and rilpivirine long-acting injectable (CAB+RPV LA) for HIV treatment in US healthcare settings; final patient and provider data M Czarnogorski On-Demand Oral Abstract Presentation View Abstract
View Presentation
Download Presentation
CAB+RPV LA implementation outcomes and acceptability of monthly clinic visits improved during COVID-19 pandemic across US healthcare clinics (CUSTOMIZE: Hybrid III Implementation-Effectiveness Study) M Czarnogorski E-Poster View Abstract
View Presentation
Download Presentation
Clinical outcomes during CUSTOMIZE: a hybrid III implementation-effectiveness study focused on implementation of cabotegravir plus rilpivirine (CAB+RPV) LA in US healthcare settings G Sinclair E-Poster View Abstract
View Presentation
Download Presentation
CABOTEGRAVIR Long-Acting for PrEP
High interest in long-acting injectable HIV pre-exposure prophylaxis among nationwide sample of men who have sex with men in the US: AMIS 2019 T Sanchez E-Poster View Abstract
Download Presentation
Estimated long-acting PrEP effectiveness in the HPTN 084 cohort using a model-based HIV incidence in the absence of PrEP M Moore On-Demand Oral Abstract Presentation View Abstract
Understanding participant experiences and preferences in an injectable PrEP trial: a qualitative sub-study of barriers, facilitators, and preferences for PrEP use among MSM and TGW C Psaros Oral Presentation View Abstract
Long-acting Injectable PrEP in Women: laboratory analysis of HIV Infections in HPTN 084. S Delany-Moretlwe E-Poster View Abstract
Preferences for Implementing Long-Acting Injectable Pre-Exposure Prophylaxis among Cisgender Men Who have Sex with Men in the US S Wilson Beckham Oral Presentation View Abstract
View Presentation
Download Presentation
Variation in preferences for long-acting injectable PrEP among US men who have sex with men: A latent class analysis S Wilson Beckham On-Demand Oral Abstract Presentation View Abstract
View Presentation
Download Presentation
FOSTEMSAVIR
Antiretroviral agents used in optimized background therapy with fostemsavir in heavily treatment-experienced adults with HIV-1: exploratory analyses of the phase 3 BRIGHTE study P Ackerman E-Poster View Abstract
View Presentation
Download Presentation
Long-term (96 week) safety of fostemsavir (FTR) in heavily-treatment experienced (HTE) adults infected with multi-drug resistance (MDR) HIV-1 (BRIGHTE phase 3 study) B Shepherd E-Poster View Abstract
View Presentation Download Presentation

Meldungen

Ältere Meldungen weiter

Diese Website bietet aktuelle Informationen zu HIV/Aids sowie zur HIV/HCV-Koinfektion. Im Mittelpunkt stehen HIV-Test, Symptome und Auswirkungen der HIV-Infektion, Behandlung der HIV-Infektion, HIV-Medikamente mit Nebenwirkungen und Komplikationen, Aids, Hepatitis B und C. Ein Verzeichnis der Ärzte mit Schwerpunkt HIV ergänzt das Angebot.